ClinicalTrials.Veeva

Find clinical trials for Multiple Myeloma in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Leukemia
Cancer
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Hanyang, Seoul, KOR:

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Phase 3

Janssen
Janssen

Seoul, Korea, Republic of and 145 other locations

of belantamab (bela) in participants with relapsed or refractory multiple myeloma (RRMM).Part 2: The primary purpose of this part i...

Enrolling
Multiple Myeloma
Drug: Belamaf
Drug: Standard of Care

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 16 other locations

of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and ...

Enrolling
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 21 other locations

Locations recently updated

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Lenalidomide

Phase 3

Pfizer
Pfizer

Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of and 206 other locations

phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 34 other locations

with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).All eligible subjects must be previously treate...

Active, not recruiting
Multiple Myeloma
Drug: CC-92480
Drug: Dexamethasone

Phase 1, Phase 2

Celgene
Celgene

Seoul, Korea, Republic of and 53 other locations

(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Belantamab mafodotin

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 150 other locations

antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...

Enrolling
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 25 other locations

compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy an...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab IV

Phase 3

Janssen
Janssen

Seoul, Korea, Republic of and 164 other locations

Locations recently updated

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Iberdomide

Phase 3

Celgene
Celgene

Seoul, Korea, Republic of and 256 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems